Tamtam Try Tamtam free
BD logo

BD account plan

Advancing global health solutions

At a glance

BD (Becton, Dickinson and Company) is a US medical technology company with FY2025 revenues of $21.840 billion and about 72,000 associates in 61 countries.

Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, develops, manufactures and sells medical supplies, devices and drug-delivery products to hospitals, clinicians, pharmacies and the pharmaceutical industry. In FY2025 (year to September 30, 2025) revenues were $21.840 billion, up 8.2%, with net income from continuing operations of $1,678 million; it employed about 72,000 associates in 61 countries. On February 9, 2026 BD completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters, receiving a $4 billion cash distribution. The remaining "New BD" reports four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.

Business units

Strategic priorities

Excellence Unleashed strategy
The New BD strategy rests on three priorities: compete (gain share in the fastest-growing areas of medtech), innovate (a more focused pipeline) and deliver (safety, quality, reliable supply and cash flow).
Commercial investment
Under its first Chief Revenue Officer, Mike Feld, BD put about $35 million of incremental commercial investment into targeted areas, growing the US APM and PI sales teams by 15% and deploying AI tools to sales reps.
Growth platforms
BD is reallocating R&D to connected care, lower-cost care settings and chronic disease; biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration grew double digits in Q3 FY2026.
GLP-1 drug delivery
BioPharma Systems has approximately 100 agreements signed across novel and biosimilar GLP-1 programs, and biologics are about 55% of Pharmaceutical Systems revenue.
BD Excellence productivity
The manufacturing network has been cut to around 50 sites, plants deliver approximately 8% gross productivity, and a $200 million cost-out program was at a $150 million run rate in Q2 FY2026.
Capital allocation
Buybacks are the top priority while net leverage of approximately 2.9x is brought toward a 2.5x target, with a 90% free cash flow conversion target over time.

Latest results

In Q3 FY2026 (quarter ended June 30, 2026), BD's first full quarter after the Waters transaction, revenues were $4.983 billion, up 5.4% reported and 4.4% FXN; adjusted operating margin was 24.9% and adjusted EPS $3.23. Gross profit margin fell to 46.4% from 47.3% on tariffs, labor costs and El Paso charges. Nine-month operating cash flow rose to $2.104 billion and total debt fell to $16,808 million. FY2026 guidance was raised to revenue growth toward the high end of the low single-digit FXN range, an adjusted operating margin of approximately 25% and adjusted EPS of $12.62 to $12.72. FY2027 is framed as low single-digit revenue growth because of a 200 basis point Alaris headwind.

Investments and deals

Waters combination
The Biosciences and Diagnostic Solutions business was spun off and combined with Waters on February 9, 2026; BD shareholders received 39.2% of the combined company and BD used the $4 billion cash distribution for $2 billion of share repurchases and $2 billion of debt repayment.
Advanced Patient Monitoring acquisition
Edwards Lifesciences' Critical Care product group was acquired on September 3, 2024 for $3.914 billion.
AI-enabled products
Pyxis Pro, the first AI-enabled Pyxis, is launching, and the BD Incada AI platform will connect Alaris, Pyxis and Advanced Patient Monitoring.
Digital supply chain platform
BD has begun deploying a standardized digital platform designed to run AI across its end-to-end supply chain.
Sterilization technology
BD is investing in new sterilization technology to meet EPA ethylene oxide rules.

Challenges and risks

FDA quality actions
The El Paso plant making ChloraPrep and PurPrep received an FDA Warning Letter on April 30, 2026; the Alaris infusion pump consent decree remains in force.
Tariffs and input costs
Tariffs cost about 110 basis points of margin in Q3 FY2026, and BD estimated that oil above $100 would mean about a $60 million to $70 million impact on COGS.
China, vaccines and Alaris
China volume-based procurement and lower vaccine demand weigh on growth, and the end of Alaris remediation creates a 200 basis points headwind in FY2027.
Pricing and reimbursement pressure
GPO and health-system consolidation and CMS's proposed expansion of competitive bidding pressure prices.
Cybersecurity
Connected products and legacy IT increase BD's cyber exposure.

What leadership says

“Through BD Excellence, we've built one of the most resilient supply chains in our industry with back orders at record lows and service levels at record highs.”

Thomas E. Polen, Chairman, CEO and President · Q3 fiscal 2026 earnings call, August 6, 2026

“we now have approximately 100 agreements signed across novel and biosimilar GLP-1 programs”

Thomas E. Polen, Chairman, CEO and President · Q3 fiscal 2026 earnings call, August 6, 2026

“We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. This was our first full quarter operating as New BD.”

Thomas E. Polen, Chairman, CEO and President · Q3 fiscal 2026 earnings call, August 6, 2026

Where a supplier can help

Quality remediation support
Tied to the El Paso Warning Letter: independent quality assessment, sterility assurance, contamination control and laboratory compliance providers fit BD's commitment to remediate the site.
Supply chain AI and data
Tied to the digital supply chain platform investment: software, data integration and analytics vendors can support the AI platform BD is deploying across its supply chain.
Sales enablement tools
Tied to the commercial investment priority: CRM, sales compensation and AI sales tools fit BD's change of rep compensation and tooling under its Chief Revenue Officer.
GLP-1 capacity
Tied to the GLP-1 drug delivery priority: suppliers of components, automation and manufacturing capacity for prefillable syringes and pens can support the roughly 100 GLP-1 programs.
Cost and tariff mitigation
Tied to the tariff and input-cost challenge: sourcing, resin hedging and logistics partners can help BD offset tariff and oil-linked cost increases.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like BD?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about BD

What does BD do?

BD develops, manufactures and sells medical supplies, devices and drug-delivery systems, including IV catheters, BD Vacutainer blood collection, BD Alaris infusion pumps, BD Pyxis dispensing, prefillable syringes and interventional products, to hospitals, pharmacies and pharmaceutical companies.

What is BD's revenue?

FY2025 revenues were $21.840 billion, up 8.2%. In Q3 FY2026, after the Waters transaction, quarterly revenues were $4.983 billion.

How many employees does BD have?

BD employed approximately 72,000 associates in 61 countries as of September 30, 2025.

Who leads BD?

Thomas E. Polen is Chairman, Chief Executive Officer and President; Vitor Roque is Executive Vice President and CFO.

What is BD's strategy?

Under "Excellence Unleashed", BD aims to compete, innovate and deliver: gain share in fast-growing medtech areas, focus its pipeline on connected care and chronic disease, and use BD Excellence for supply and margin.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)